10.02.15
London, United Kingdom-based Lumenis Ltd., an energy-based medical device company for surgical, aesthetic and ophthalmic applications, has released of Lumenis Pulse 100H and Lumenis Pulse 50H.
The Lumenis Pulse 100H, the next generation of the Versapulse Powersuite 100 watt system, is an enhanced laser solution for the treatment of an array of clinical urologic indications including benign prostatic hyperplasia (BPH), stones, tumors or strictures, along with a range of other specialties such as general surgery, ear nose and throat, gynecology and pulmonary surgery. The Pulse 100H enables users to perform holmium laser enucleation of the prostate (HoLEP), the gold standard treatment for BPH, and stone dusting, a method whereby the stones are broken into tiny fragments or “dust” so that the stones can pass spontaneously.
The new system features an improved design to enhance patient safety and overall user experience. It offers a combination of laser parameters addressing more than 70 types of procedures, an innovative pulse reshape function for improved safety, dual pedals for improved ease of use, a hands-free ready and standby mode for minimizing cost per procedure, and a high energy per pulse of up to 3.5 J with a high repetition rate of up to 50 Hz.
In addition to the Pulse 100H, Lumenis will also be unveiling another key addition to the Lumenis Pulse laser family, the Pulse 50H laser system. Designed to efficiently address any type or size of stone in lithotripsy (the method by which stones are broken down via ultrasound shock waves), the Pulse 50H system is a touted as a comprehensive solution that provides 0.2 J of energy per pulse to minimize migration of even the smallest stone. Furthermore, the Pulse 50H can be later upgraded to the new Pulse 100H, allowing physicians to further leverage their investment as they grow their practice, company officials note.
“With our commitment to the Endourological Society, we are proud to present two new innovative systems, the Pulse 100H and 50H, to meet the developing, dynamic market need in the field of minimally invasive urological surgery,” said Tzipi Ozer-Armon, CEO of Lumenis. “The additions to the Pulse platform series signify a key improvement to our current urological solutions for HoLEP and stone dusting and empower users to achieve more than 70 types of procedures in a range of clinical specialties.”
The Lumenis Pulse 100H, the next generation of the Versapulse Powersuite 100 watt system, is an enhanced laser solution for the treatment of an array of clinical urologic indications including benign prostatic hyperplasia (BPH), stones, tumors or strictures, along with a range of other specialties such as general surgery, ear nose and throat, gynecology and pulmonary surgery. The Pulse 100H enables users to perform holmium laser enucleation of the prostate (HoLEP), the gold standard treatment for BPH, and stone dusting, a method whereby the stones are broken into tiny fragments or “dust” so that the stones can pass spontaneously.
The new system features an improved design to enhance patient safety and overall user experience. It offers a combination of laser parameters addressing more than 70 types of procedures, an innovative pulse reshape function for improved safety, dual pedals for improved ease of use, a hands-free ready and standby mode for minimizing cost per procedure, and a high energy per pulse of up to 3.5 J with a high repetition rate of up to 50 Hz.
In addition to the Pulse 100H, Lumenis will also be unveiling another key addition to the Lumenis Pulse laser family, the Pulse 50H laser system. Designed to efficiently address any type or size of stone in lithotripsy (the method by which stones are broken down via ultrasound shock waves), the Pulse 50H system is a touted as a comprehensive solution that provides 0.2 J of energy per pulse to minimize migration of even the smallest stone. Furthermore, the Pulse 50H can be later upgraded to the new Pulse 100H, allowing physicians to further leverage their investment as they grow their practice, company officials note.
“With our commitment to the Endourological Society, we are proud to present two new innovative systems, the Pulse 100H and 50H, to meet the developing, dynamic market need in the field of minimally invasive urological surgery,” said Tzipi Ozer-Armon, CEO of Lumenis. “The additions to the Pulse platform series signify a key improvement to our current urological solutions for HoLEP and stone dusting and empower users to achieve more than 70 types of procedures in a range of clinical specialties.”